Chemically defined peptide conjugation to whole IgG, monoclonal antibodies, antibody fragments, and engineered formats—with practical coupling routes and program‑aligned analytics.
Bio-Synthesis provides peptide–antibody conjugation services for programs requiring controlled peptide attachment to intact IgG, monoclonal antibodies, and antibody fragments (Fab, F(ab’)₂, scFv formats). We routinely support peptide–IgG conjugation, peptide–monoclonal antibody (mAb) conjugation, and workflows that combine antibody fragmentation and conjugation (e.g., Fab or F(ab’)₂) when a fragment format is preferred. We support both rapid feasibility constructs and more controlled, site-defined designs using practical chemistries (amine, thiol, and copper‑free click).
Unlike ADC-only workflows, peptide–antibody conjugates are often designed for targeting concepts, assay reagents, hybrid binding tools, or functional studies. We implement your design, purify the conjugate, and provide fit‑for‑purpose analytical verification aligned to your program stage.
We support peptide conjugation to intact antibodies and common fragment formats. If your program benefits from a fragment, we can also support antibody fragmentation (format‑dependent) prior to conjugation.
Peptide motifs may include targeting ligands or CPP-like sequences. Selection should be evaluated experimentally for binding retention, stability, and off‑target interactions. We implement the chemistry and provide analytical confirmation of the conjugate without implying biological performance outcomes.
We can conjugate your supplied peptide design or synthesize a peptide with a site-defined handle to enable controlled attachment (N‑terminus, Lys, Cys, or internal handle). Examples of peptide classes commonly used on antibody scaffolds include:
If you want minimal perturbation, we can help place the handle away from functional residues and propose a short spacer/linker length consistent with your intended use.
Conjugation chemistry is selected based on antibody format, peptide handle, and desired control of attachment site. We support practical routes used for protein bioconjugation, including:
Linker choice can impact conjugate integrity and storage; we confirm compatibility with your buffer/stabilizers.
Most peptide–antibody conjugations are performed in solution phase after peptide synthesis and handle installation. When site control is required, engineered handles (unique Cys or click-ready groups) can enable more defined attachment.
Compared with ADC programs, peptide–antibody conjugates often emphasize functional peptides and defined characterization for binding/targeting concepts or assay workflows rather than cytotoxic payload delivery.
We can scale and qualify based on intended use; acceptance criteria should be defined for your downstream application.
Conjugate profile depends on antibody format and chemistry. We align a practical analytics package to your intended use.
Bio-Synthesis is committed to fit‑for‑purpose quality systems to support reproducible research reagents and program development. We align purification, analytics, and documentation to your stage and intended use with traceable records and clear reporting.
Common end-to-end builds: peptide–IgG conjugation, peptide–mAb conjugation, and fragmentation → conjugation for Fab/F(ab’)₂ constructs.
If your program includes upstream antibody processing or adjacent conjugation formats, these services can be bundled into a single, traceable workflow.
Need a specific antibody format (IgG subclass, Fab/F(ab’)₂, scFv, VHH) or a particular attachment strategy? Share the format, concentration/buffer, and target DAR/loading goals—we’ll recommend a practical route.
Yes. We support peptide conjugation to whole IgG and monoclonal antibodies using practical solution-phase coupling routes (amine, thiol, and copper‑free click), with fit‑for‑purpose analytics aligned to your program needs.
Yes. We can conjugate to supplied fragments and can also support optional antibody fragmentation (format‑dependent) prior to peptide coupling. Chemistry is selected to preserve binding and maintain construct integrity.
No. ADCs are a specific class of antibody conjugates built around cytotoxic payloads and DAR control. Peptide–antibody conjugates are often designed for targeting concepts, detection, and functional studies. Chemistry overlaps, but intent and characterization priorities can differ.
Send antibody format, concentration and buffer (including stabilizers), peptide sequence and desired handle/attachment site, preferred chemistry (if known), and target deliverables (scale, purification, QC/data package).
Yes. We support peptide conjugation to intact IgG (including different subclasses) and to monoclonal antibodies using amine, thiol, or copper‑free click strategies, with purification and fit‑for‑purpose analytics aligned to your intended use.
Yes. For suitable antibodies, we can support fragmentation (e.g., Fab or F(ab’)₂ generation), purification/conditioning, and subsequent peptide conjugation. We select coupling conditions to maintain fragment integrity and binding performance, and provide stage‑appropriate analytical verification.
If your program spans additional conjugate types, these pages can help with handle planning and cross‑linking options:
Need oligonucleotide conjugation? See peptide–DNA, peptide–ASO, peptide–siRNA pages in the oligonucleotide conjugation hub.
References are provided for context and method planning; program acceptance criteria should be set for your intended use.
Trusted by biotech leaders worldwide for over 40+ years of delivering high quality, fast and scalable synthetic biology solutions.